AMLX — Amylyx Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $1.61bn
- $1.27bn
- $87.37m
- 38
- 19
- 72
- 38
Annual cashflow statement for Amylyx Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -42.3 | -87.9 | -198 | 49.3 | -302 |
| Depreciation | |||||
| Non-Cash Items | 2.98 | 8.34 | 20.1 | 27.2 | 179 |
| Unusual Items | |||||
| Purchased R&D | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 2.6 | 4.74 | -2.13 | -65.7 | -45.8 |
| Change in Accounts Receivable | |||||
| Change in Inventories | |||||
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Cash from Operating Activities | -36.7 | -74.8 | -180 | 11.9 | -168 |
| Capital Expenditures | -0.151 | -0.353 | -2.53 | -1.24 | -36.4 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | -46.1 | -236 | 93.3 | 112 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | -0.151 | -46.4 | -239 | 92.1 | 75.7 |
| Financing Cash Flow Items | 1.16 | -2.73 | -2.85 | -3.45 | -1.78 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 46.8 | 159 | 432 | 3.54 | 0.348 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 9.97 | 37.3 | 12.9 | 108 | -92.1 |